Researchers Develop New Avian Metapneumovirus Vaccine

A new $250,000 research project targets respiratory disease in U.S. poultry flocks.

Updated on Oct. 20, 2026 in Veterinary Medicine

A glass medical vial containing a clear sample on a clean stainless steel lab surface. — South Dakota State University researchers are developing a new vaccine against avian metapneumovirus to protect U.S. poultry flocks from respiratory illness. AI Illustration. Upload story photo >

Live Poll

Should the government prioritize funding for research into vaccine solutions for agricultural diseases?

South Dakota State University researchers are working to develop a vaccine specifically for U.S. strains of avian metapneumovirus. The project aims to improve upon existing imported vaccines that utilize European virus variants.

Why it matters

Avian metapneumovirus causes significant respiratory illness in chickens and turkeys, leading to notable economic losses for poultry producers. Creating a vaccine tailored to domestic strains may offer better protection than current imported options.

The research team secured a $250,000 investment to develop a vaccine candidate that is more than 99% genetically identical to domestic aMPV-B strains. Studies are testing vaccine efficacy through spray, oral, and eye-drop administration.

The players

South Dakota State University

A public research university that serves as the primary site for this avian metapneumovirus vaccine study.

Foundation for Food & Agriculture Research

A nonprofit organization that builds public-private partnerships to fund food and agriculture research.

USPOULTRY

The U.S. Poultry & Egg Association is a professional organization representing the interests of the poultry industry.

The details

Researchers are evaluating how imported vaccines based on European strains compare to a new candidate derived from a U.S. poultry farm aMPV-B strain. The team is conducting trials in chickens and turkeys to determine the most effective delivery methods and long-term immunity.

Late 2023 marked the emergence of aMPV subtypes A and B in the United States.
Early 2024 saw the continued spread of these virus subtypes across the country.
October 2026 brought the official announcement of the $250,000 research investment.

Culture Shift

This research follows the regulatory path established by the U.S. Department of Agriculture conditional approval protocols for veterinary vaccines to bring new solutions to market. It highlights a growing shift toward developing location-specific veterinary countermeasures rather than relying on imported legacy products.

This research could eventually provide poultry producers in South Dakota and across the nation with a more reliable way to protect their flocks from respiratory disease. Better vaccine efficacy may lead to reduced losses and improved stability in the local poultry market.

The takeaway

Developing a vaccine that matches local viral strains is crucial for effective disease management in agriculture. Producers should monitor ongoing studies for updates on vaccine availability and recommended administration techniques.